

PATENT

224/090

12. (Amended) A method for modulating a process selectively mediated by one or more Retinoid X Receptors, said method comprising causing said process to be conducted in the presence of at least one compound which selectively activates a Retinoid X Receptor in preference to [a] all of Retinoic Acid Receptor isoforms  $\alpha$ ,  $\beta$ , and  $\gamma$ .

13. (Amended) A method for treating a mammalian subject requiring Retinoid X Receptor therapy comprising administering to such subject a pharmaceutically effective amount of one or more compounds which selectively activate a Retinoid X Receptor in preference to [a] all of Retinoic Acid Receptor isoforms  $\alpha$ ,  $\beta$ , and  $\gamma$ .

### REMARKS

Claims 1-13 of this application have been allowed by the Notice of Allowance mailed August 7, 1998. Applicants hereby respectfully request consideration and entry of this amendment pursuant to 37 CFR § 1.312(a) to the allowed claims of this application, which will not require any additional search or examination.

Specifically, amendment of claims 12 and 13 is requested, as shown above, to expressly state that compound used or contained in each claim, which compound selectively activates a Retinoid X Receptor in preference to a Retinoic Acid Receptor, further is specified to selectively activate a Retinoid X Receptor in preference to all of Retinoic Acid Receptor isoforms  $\alpha$ ,  $\beta$ , and  $\gamma$ .

The support for this amendment is found in the specification in the examples of Tables 1, 2, 3 on pages 66 and 68-69 and on page 71 of the specification, which show that the specified